Cargando…

Modifiable risk factors of COVID-19 in patients with multiple sclerosis: a single-centre case–control study

BACKGROUND: Disease and treatment-associated immune system abnormalities may confer higher risk of Coronavirus disease 2019 (COVID-19) to people with multiple sclerosis (PwMS). We assessed modifiable risk factors associated with COVID-19 in PwMS. METHODS: Among patients referring to our MS Center, w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Montini, Federico, Nozzolillo, Agostino, Rancoita, Paola M. V., Zanetta, Chiara, Moiola, Lucia, Cugnata, Federica, Esposito, Federica, Rocca, Maria A., Martinelli, Vittorio, Filippi, Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Original Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9933018/ https://www.ncbi.nlm.nih.gov/pubmed/36795147 http://dx.doi.org/10.1007/s00415-023-11618-0

Ejemplares similares

Prognostic factors related to the risk of COVID-19 infection in MS patients
por: Montini, Federico, et al.
Publicado: (2021)

COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience
por: Preziosa, Paolo, et al.
Publicado: (2020)

Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing–remitting multiple sclerosis patients: a monocentric longitudinal observational study
por: Zanetta, Chiara, et al.
Publicado: (2023)

Correction to: Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing–remitting multiple sclerosis patients: a monocentric longitudinal observational study
por: Zanetta, Chiara, et al.
Publicado: (2023)

Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience
por: S., Guerrieri, et al.
Publicado: (2021)

Risk HLA Variants Affect the T-Cell Repertoire in Multiple Sclerosis
por: Sorosina, Melissa, et al.
Publicado: (2023)

Atrioventricular block after fingolimod resumption: a consequence of sphingosine-1-phosphate axis alteration due to COVID-19?
por: Orrico, Mario, et al.
Publicado: (2021)

Combining Clinical and Genetic Data to Predict Response to Fingolimod Treatment in Relapsing Remitting Multiple Sclerosis Patients: A Precision Medicine Approach
por: Ferrè, Laura, et al.
Publicado: (2023)

Stress related to COVID-19 pandemic as a trigger for disease activity in multiple sclerosis: a case report
por: Giordano, Antonino, et al.
Publicado: (2021)

Slowly Expanding Lesions Predict 9-Year Multiple Sclerosis Disease Progression
por: Preziosa, Paolo, et al.
Publicado: (2022)

Involvement of Genetic Factors in Multiple Sclerosis
por: Ferrè, Laura, et al.
Publicado: (2020)

COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: Implication for vaccination program?
por: Gelibter, Stefano, et al.
Publicado: (2021)

Safety of Natalizumab infusion in multiple sclerosis patients during active SARS-CoV-2 infection
por: Landi, Doriana, et al.
Publicado: (2022)

The Communication of Multiple Sclerosis Diagnosis: The Patients' Perspective
por: Messina, Maria Josè, et al.
Publicado: (2015)

Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (clippers) after COVID-19
por: Montini, Federico, et al.
Publicado: (2021)

Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) after SARS-CoV-2 pneumonia
por: Montini, Federico, et al.
Publicado: (2021)

Physical Exercise Moderates the Effects of Disability on Depression in People with Multiple Sclerosis during the COVID-19 Outbreak
por: Carotenuto, Antonio, et al.
Publicado: (2021)

Changes in cortical motor outputs after a motor relapse of multiple sclerosis
por: Chieffo, Raffaella, et al.
Publicado: (2019)

Free Light Chains and Intrathecal B Cells Activity in Multiple Sclerosis: A Prospective Study and Meta-Analysis
por: Passerini, Gabriella, et al.
Publicado: (2016)

Exploring the Association of HLA Genetic Risk Burden on Thalamic and Hippocampal Atrophy in Multiple Sclerosis Patients
por: Santoro, Silvia, et al.
Publicado: (2022)

Inferring Multiple Sclerosis Stages from the Blood Transcriptome via Machine Learning
por: Acquaviva, Massimo, et al.
Publicado: (2020)

Loss of Circulating CD8+ CD161(high) T Cells in Primary Progressive Multiple Sclerosis
por: Acquaviva, Massimo, et al.
Publicado: (2019)

Discovering functional connectivity features characterizing multiple sclerosis phenotypes using explainable artificial intelligence
por: Yamin, Muhammad Abubakar, et al.
Publicado: (2023)

In vivo structural and functional assessment of optic nerve damage in neuromyelitis optica spectrum disorders and multiple sclerosis
por: Vabanesi, Marco, et al.
Publicado: (2019)

Myeloid cells as target of fingolimod action in multiple sclerosis
por: Di Dario, Marco, et al.
Publicado: (2015)

Sexual Dysfunction in People with Multiple Sclerosis: The Role of Disease Severity, Illness Perception, and Depression
por: Scandurra, Cristiano, et al.
Publicado: (2023)

Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab
por: Diotti, Roberta Antonia, et al.
Publicado: (2016)

Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets
por: Moiola, Lucia, et al.
Publicado: (2022)

Network Damage Predicts Clinical Worsening in Multiple Sclerosis: A 6.4-Year Study
por: Rocca, Maria A., et al.
Publicado: (2021)

Structural MRI outcomes and predictors of disease progression in amyotrophic lateral sclerosis
por: Spinelli, Edoardo G., et al.
Publicado: (2020)

Involvement of NINJ2 Protein in Inflammation and Blood–Brain Barrier Transmigration of Monocytes in Multiple Sclerosis
por: Sorosina, Melissa, et al.
Publicado: (2022)

Time-varying connectivity of the precuneus and its association with cognition and depressive symptoms in neuromyelitis optica: A pilot MRI study
por: Cacciaguerra, Laura, et al.
Publicado: (2022)

Contribution of Rare and Low-Frequency Variants to Multiple Sclerosis Susceptibility in the Italian Continental Population
por: Clarelli, Ferdinando, et al.
Publicado: (2022)

The Role of T1-Weighted Derived Measures of Neurodegeneration for Assessing Disability Progression in Multiple Sclerosis
por: Rocca, Maria A., et al.
Publicado: (2017)

Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis
por: Sormani, Maria P., et al.
Publicado: (2021)

Cortico-efferent tract involvement in primary lateral sclerosis and amyotrophic lateral sclerosis: A two-centre tract of interest-based DTI analysis
por: Müller, Hans-Peter, et al.
Publicado: (2018)

Depressive symptoms, anxiety and cognitive impairment: emerging evidence in multiple sclerosis
por: Margoni, Monica, et al.
Publicado: (2023)

An Investigation of the Role of Common and Rare Variants in a Large Italian Multiplex Family of Multiple Sclerosis Patients
por: Barizzone, Nadia, et al.
Publicado: (2021)

Anti-CD20 therapies for multiple sclerosis: current status and future perspectives
por: Margoni, Monica, et al.
Publicado: (2021)

Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus
por: Centonze, Diego, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_up2u7ics8k5aa5otfgnmhkgbm8